Press Release Jun 02 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received tentative approval from the USFDA for Rifaximin Tablets, which are used to treat irritable bowel syndrome with diarrhoea in adults. The approval allows Zydus to produce these tablets at its manufacturing site in Ahmedabad. The press release highlights that Rifaximin tablets had significant annual sales in the United States, indicating a strong market potential for the product.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release May 28 2025
- Press Release May 23 2025
- Press Release May 20 2025
- Press Release May 14 2025
- Press Release May 08 2025
Later from Zydus Lifesciences
- Press Release Jun 10 2025
- Press Release Jun 11 2025
- Press Release Jun 18 2025
- Press Release Jul 15 2025
- Press Release Jul 16 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences